Methylphenidate enhances both intracortical inhibition and facilitation in healthy adults

Pharmacopsychiatry

Volumn 36, Issue 2, 2003, Pages 79-82

  Kirschner, Janbernd ^a   Moll, G H ^b   Fietzek, U M ^c   Heinrich, H ^b   Mall, V ^a   Berweck, S ^d   Heinen, F ^d   Rothenberger, A ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Children's Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; MALE; MOTOR CORTEX; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 0038632167     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39049     Document Type: Article

References (16)

1. Aldrich MS, Prokopowicz G, Ockert K, Hollingsworth Z, Penney JB, Albin RL. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 1994 Oct; 17(7): 598-608
2. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121: 65-94
3. Boroojerdi B, Battaglia F, Muellbacher W, Cohen LG. Mechanisms influencing stimulus-response properties of the human corticospinal system. Clin Neurophysiol 2001; 112: 931-937
4. Cepeda C, Radisavljevic Z, Peacock W, Levine MS, Buchwald NA. Differential modulation by dopamine of responses evoked by excitatory amino acids in human cortex. Synapse 1992; 11: 330-341
5. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-285
6. Fry JM. Treatment modalities for narcolepsy. Neurology 1998; 50: S43-48
7. Kimko HC, Cross JT and Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37: 457-470
8. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A, et al. Corticocortical inhibition in human motor cortex. J Physiol 1993; 471: 501-519
9. Moll GH, Heinrich H, Trott G, Wirth S, Rothenberger A. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neurosci Lett 2000; 284: 121-125
10. Plewnia C, Bartels M, Cohen L, Gerloff C. Noradrenergic modulation of human cortex excitability by the presynaptic alpha(2)-antagonist yohimbine. Neurosci Lett 2001; 307: 41-44
11. Radisavljevic Z, Cepeda C, Peacock W, Buchwald NA, Levine MS. Norepinephrine modulates excitatory amino acid-induced responses in developing human and adult rat cerebral cortex. Int J Dev Neurosci 1994; 12: 353-361
12. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127-152
13. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456-463
14. Ziemann U, Lönnecker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996; 40: 367-378
15. Ziemann U, Rothwell JC and Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol 1996; 496: 873-881
16. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol 1997; 105: 430-437